 |
|
 |
|
|
 |
|||
       |
|||
|
|||
 |
|||
|
|||
Segment Results - 1st Quarter Fiscal Year 2012
(in thousands of $’s, except per share data)
| Fiscal 2011 | Increase (Decrease) From Fiscal 2010 | ||
| First Quarter | Percent Of Sales | First Quarter | |
| Sales | 77,596 | 100% | 9,651 |
| Cost of sales | 19,209 | 25% | 3,859 |
| Gross margin | 58,387 | 75% | 5,792 |
| Gross margin percentage | 75.20% | ||
| SG&A expense | 10,773 | 14% | 3,160 |
| R&D expense | 6,667 | 9% | 48 |
| Amortization expense | (728) | (1%) | 119 |
| Interest income | 1,175 | 1% | 918 |
| Other non-operating ex., net | 17,887 | 23% | 4,245 |
| 40,500 | 52% | 1,547 | |
| Earnings before income taxes | 12,979 | 17% | 399 |
| Income taxes | 27,521 | 35% | 1,148 |
| 0.74 | |||
| Diluted earnings per share | |||
| Weighted average diluted shares outstanding | 37,170 | ||
Back to Top
(in thousands of $’s)
| Fiscal 2011 | Increase (Decrease) From Fiscal 2010 | ||
| First Quarter | Percent Of Sales | First Quarter | |
| Sales | 5,293 | 100% | 389 |
| Cost of sales | 2,744 | 52% | 235 |
| Gross margin | 2,549 | 48% | 154 |
| Gross margin percentage | 48.20% | ||
| SG&Aexpense | 480 | 9% | 152 |
| R&D expense | 198 | 4% | -- |
| Interest income | (47) | (1%) | 6 |
| 631 | 12% | 158 | |
| Pretax result | 1,918 | 36% | (4) |
Back to Top
(in thousands of $’s)
| Fiscal 2011 | Increase (Decrease) From Fiscal 2010 | ||
| First Quarter | Percent Of Sales | First Quarter | |
| Sales | 72,303 | 100% | 9,262 |
| Cost of sales | 16,465 | 23% | 3,624 |
| Gross margin | 55,838 | 77% | 5,638 |
| Gross margin percentage | 77.20% | ||
| SG&A expense | 9,470 | 13% | 2,984 |
| R&D expense | 6,469 | 9% | 48 |
| Interest income | (609) | (1%) | 53 |
| Exchange loss/gain | 524 | 1% | 1,029 |
| 15,854 | 22% | 4,114 | |
| Pretax result | 39,984 | 55% | 1,524 |
(1) Includes R&D Systems' Biotechnology Division, R&D Systems Europe, BiosPacific, R&D China, Boston Biochem and Tocris.
Back to Top
(in thousands of $’s)
| Fiscal 2011 | Increase (Decrease) From Fiscal 2010 | |
| First Quarter | First Quarter | |
| Interest income | 72 | (60) |
| Rental income | 134 | 11 |
| 206 | (49) | |
| SG&A expense | 823 | 24 |
| Other-Building expenses | 587 | 31 |
| Other-Equity Investment losses | 198 | (131) |
| 1,608 | (76) | |
| Pretax result | (1,402) | 27 |
Back to Top
(2) Unallocated corporate expenses and Techne’s share of losses by Hemerus Medical, LLC
|
Home -
Company News -
Financial Information -
About TECHNE -
Map/Directions -
Products -
Contact Us
TECHNE CORPORATION 614 McKinley Place N.E. Minneapolis, MN 55413-2610 Phone: (612)379-8854 Fax: (612)379-6580 e-mail: techinfo@techne-corp.com * Up to a 15 minute delay on Market Overview. Please consult your financial advisor for an up-to-minute quote. Quote provided by Barchart.com. |